Breaking WORLD PHARMA NEWS

Plastic bottles transformed into Parkinson’s drug using bacteria

A drug to treat Parkinson’s disease can be made from waste plastic bottles using a pioneering method, a study shows.

The approach harnesses the power of bacteria to transform post-consumer plastic into L-DOPA, a frontline medication for the neurological disorder.

Read more …

Researchers break decades-old bottleneck in chemotherapy drug manufacturing

An international team of researchers has achieved a breakthrough in the production of doxorubicin, a vital chemotherapy agent. The study identifies and resolves molecular "bottlenecks" that have limited the natural production of this drug for over 50 years.

Doxorubicin is a chemotherapy drug that was first approved for medical use in the 1970s.

Read more …

Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of neurological manifestations of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder.

Read more …

Preclinical study reveals new cream may prevent or slow growth of some common skin cancers

A topical cream activated the skin’s immune defenses and suppressed tumor growth in two preclinical models of cutaneous squamous cell carcinoma (cSCC), one of the most common cancers in the world, according to a study published in the Journal of Clinical Investigation. Developed by researchers at the Perelman School of Medicine at the University of Pennsylvania, the cream works by blocking LSD1, an enzyme that suppresses immune‑activating pathways in the skin.

Read more …

Safer blood clot treatment with apixaban than with rivaroxaban

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications.

Venous thrombosis occurs when a blood clot lodges in the veins of the legs or lungs.

Read more …

Experimental chemo drug may trick the immune system into fighting cancer

A new discovery from researchers at The University of Texas at Austin and The University of Texas MD Anderson Cancer Center helps explain why some chemotherapy drugs not only eliminate cancer cells directly, they - at least in some patients - actually trigger the innate immune system to attack cancer cells.

The researchers made this discovery while testing a potential chemotherapy agent referred to as Compound 1 - which causes a build-up of toxic molecules called reactive oxygen species - on preclinical models.

Read more …

New drug combination doubles down on Alzheimer's treatments

A new study finds that combining the current medications for Alzheimer’s disease with small molecules derived from micronutrients found in grapes, berries, peanuts and turmeric is a safer and more effective way to treat the disease.

Individuals with Alzheimer’s have a buildup of toxic amyloid proteins in the brain. Researchers from the School of Pharmacy at the University of Waterloo combined amyloid-destroying small molecules with anti-amyloid antibodies that are already used in Alzheimer’s treatment.

Read more …

Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'

Abbott (NYSE: ABT) announced today the launch of the second year of the 'Abbott Dream Team,' encouraging young soccer players aged 18-19 across the United States to sign up for the chance to take part in a once-in-a-lifetime development experience in Madrid. Selected participants will train with Real Madrid's world‑renowned coaches at the club's facilities and enjoy unique opportunities, including attending a Real Madrid match at the Bernabéu Stadium and meeting club legends.

Read more …

Life-changing drug identified for children with rare epilepsy

A new experimental treatment for children with a hard-to-treat form of epilepsy is safe and can reduce seizures dramatically, helping them lead much healthier and happier lives, the findings of a UCL (University College London) and Great Ormond Street Hospital-led international clinical trial show.

In a new paper published in The New England Journal of Medicine, the researchers found that children with Dravet syndrome had up to 91 per cent fewer seizures while being regularly administered a new medication called zorevunersen.

Read more …

Pfizer's Phase 2 study of trispecific antibody positive in moderate to severe atopic dermatitis

Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its primary efficacy endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥ 75% reduction in the Eczema Area and Severity Index) at Week 16, compared to placebo.

Read more …